OIS has showcased dozens of ophthalmic leaders who are part of Israel’s thriving biotech and medtech spaces. This OIS Podcast features one of those leaders, who’s preparing for MIXiii Health-Tech.IL, the annual gathering for the life science and health tech industries in Israel. It’ll be held in Jerusalem November 9 and 10. And for the first time, OIS Israel will be part of it.Podcast host Rob Rothman, MD (also an OIS Israel cochair), talks to Tarsier Pharma founder and CEO Daphne Haim-Langford, PhD. Dr. Haim-Langford gives an update on her company’s Phase III trial for TRS01, a drop designed to treat uveitis and uveitic glaucoma. The trial is 50% enrolled, she says. Meanwhile, Tarsier is conducting Investigative New Drug (IND)–enabling studies for TRS02, an injectable therapy intended to treat diabetic macular edema, dry age-related macular degeneration (AMD), and posterior uveitis.   Dr. Haim-Langford describes OIS Israel as a showcase for “groundbreaking developments that bring hope to ophthalmologists and patients” and notes that 27 different companies will present over the two days. Listen to the podcast to hear:The unique culture that makes Israel fertile ground for new technology as well as new drugs.How the ophthalmic culture in Israel allows for smooth collaboration between industry, medical centers, academia, and finance.How collaboration between these stakeholders differs from the US.Why publicly traded venture capital companies focused on ophthalmic startups have had success in Israel.Why now is the time for Israel Advanced Technology Industries (IATI) to hold an ophthalmic session at MIXiii. Click “play” to listen.